Abstract 4043: Stimulation of the mapk and pi3k/akt pathways in pancreatic cancer cells by polyisoprenylated cysteinyl amide inhibitors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4043
Abstract: Pancreatic cancer is the third deadliest cancer with a 5-year survival rate of less than 10%. Over 90% of reported cases are driven by KRAS mutations. KRAS signals through the MAPK and PI3K pathways. Targeting… read more here.
Keywords: mapk pi3k; pancreatic cancer; nsl yhj; polyisoprenylated cysteinyl ... See more keywords
Abstract 7508: Transcriptomic analysis of polyisoprenylated cysteinyl amide inhibitors treatment of pancreatic and breast cancer reveals changes in apoptotic and angiogenic factors
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-7508
Abstract: The aggressive nature of KRAS-driven cancers and the lack of effective targeted therapies makes them extremely challenging to manage. The polyisoprenylated cysteinyl amide inhibitors (PCAIs) were designed to mimic the polybasic C-terminal hypervariable (HVR) region… read more here.
Keywords: cancer; treatment; amide inhibitors; polyisoprenylated cysteinyl ... See more keywords
Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis
Sign Up to like & getrecommendations! Published in 2024 at "PLOS ONE"
DOI: 10.1371/journal.pone.0312563
Abstract: KRAS mutations are the most common oncogenic mutations in lung adenocarcinoma in Black Americans. Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress… read more here.
Keywords: cysteinyl amide; nsl yhj; yhj; cell ... See more keywords